AN2-502998

May 11, 2026 — AN2 Therapeutics, Inc. (Nasdaq: ANTX) reported Q1 2026 financial results and provided R&D updates across hematology, infectious disease, and oncology programs. The company plans to initiate a Phase 2 proof-of-concept trial of oral epetraborole in adults with phlebotomy-dependent polycythemia vera in Q3 2026, with interim readouts potentially starting in Q4 2026 and continuing through 2027. An investigator-initiated, multicenter randomized double-blind Phase 2 trial of epetraborole in Mycobacterium abscessus lung disease began screening in March 2026, with topline results anticipated in late 2027. For chronic Chagas disease, AN2 completed dosing in a Phase 1 first-in-human study of oral AN2-502998; Phase 1 results plus a non-human primate efficacy readout (28-day dosing) are expected in 2Q 2026, and a Phase 2 study is planned later in 2026 pending Phase 1 data. AN2 also declared an ENPP1 candidate for solid tumors moving into development.

Financially, Q1 2026 net loss was $10.0M (vs. $10.6M in Q1 2025); cash/investments were $85.3M as of March 31, 2026, supported by a $40.0M March private placement, with runway projected into 2029.